Multistep model of cervical cancer: Participation of miRNAs and coding genes

International Journal of Molecular Sciences

Volumn 15, Issue 9, 2014, Pages 15700-15733

  López, Angelica Judith Granados ^a   López, Jesús Adrián ^a  

^a UNIVERSIDAD AUTÓNOMA DE ZACATECAS   (Mexico)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia (CIN); miRNAs

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2C; CYSTEINE RICH PROTEIN 61; MICRORNA; MICRORNA 10B; MICRORNA 128; MICRORNA 133B; MICRORNA 143; MICRORNA 145; MICRORNA 15A; MICRORNA 16; MICRORNA 17; MICRORNA 196B; MICRORNA 199A; MICRORNA 199S; MICRORNA 21; MICRORNA 23B; MICRORNA 29A; MICRORNA 346; MICRORNA 375; MICRORNA 518B; MICRORNA 9; ONCOPROTEIN; PROTEIN BAK; PROTEIN BCL 2; PROTEIN P53; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR YY1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE; CELL IMMORTALIZATION; CELL INVASION; CELL MIGRATION; DNA METHYLATION; DOWN REGULATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC CODE; GENOMIC INSTABILITY; HUMAN; MICROARRAY ANALYSIS; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; UPREGULATION; UTERINE CERVIX CANCER; WART VIRUS; ANIMAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; UTERINE CERVIX TUMOR;

ANIMALS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; ONCOGENE PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 84908312340     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150915700     Document Type: Review

References (142)

1. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 2001, 94, 153-156.
2. Chakrabarti, O.; Krishna, S. Molecular interactions of "high risk" human papillomaviruses E6 and E7 oncoproteins: implications for tumour progression. J. Biosci. 2003, 28, 337-348.
3. DiMaio, D.; Liao, J.B. Human papillomaviruses and cervical cancer. Adv. Virus Res. 2006, 66, 125-159.
4. Dyson, N.; Howley, P.M.; Munger, K.; Harlow, E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243, 934-937.
5. Scheffner, M.; Werness, B.A.; Huibregtse, J.M.; Levine, A.J.; Howley, P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63, 1129-1136.
6. Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6, 857-866.
7. Miller, D.M.; Blume, S.; Borst, M.; Gee, J.; Polansky, D.; Ray, R.; Rodu, B.; Shrestha, K.; Snyder, R.; Thomas, S.; et al. Oncogenes, malignant transformation, and modern medicine. Am. J. Med. Sci. 1990, 300, 59-69.
8. Weinberg, R.A. Tumor suppressor genes. Science 1991, 254, 1138-1146.
9. Lim, P.K.; Bliss, S.A.; Patel, S.A.; Taborga, M.; Dave, M.A.; Gregory, L.A.; Greco, S.J.; Bryan, M.; Patel, P.S.; Rameshwar, P. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res. 2011, 71, 1550-1560.
10. Rechavi, O.; Erlich, Y.; Amram, H.; Flomenblit, L.; Karginov, F.V.; Goldstein, I.; Hannon, G.J.; Kloog, Y. Cell contact-dependent acquisition of cellular and viral nonautonomously encoded small RNAs. Genes Dev. 2009, 23, 1971-1979.
11. Dalmay, T.; Edwards, D.R. MicroRNAs and the hallmarks of cancer. Oncogene 2006, 25, 6170-6175.
12. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281-297.
13. Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136, 215-233.
14. Griffiths-Jones, S.; Saini, H.K.; van Dongen, S.; Enright, A.J. MiRBase: Tools for microRNA genomics. Nucleic Acids Res. 2008, 36, D154-D158.
15. Lewis, B.P.; Burge, C.B.; Bartel, D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120, 15-20.
16. Grimson, A.; Farh, K.K.; Johnston, W.K.; Garrett-Engele, P.; Lim, L.P.; Bartel, D.P. MicroRNA targeting specificity in mammals: Determinants beyond seed pairing. Mol. Cell 2007, 27, 91-105.
17. Baek, D.; Villen, J.; Shin, C.; Camargo, F.D.; Gygi, S.P.; Bartel, D.P. The impact of microRNAs on protein output. Nature 2008, 455, 64-71.
18. Selbach, M.; Schwanhausser, B.; Thierfelder, N.; Fang, Z.; Khanin, R.; Rajewsky, N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455, 58-63.
19. Lopez, J.A.; Alvarez-Salas, L.M. Differential effects of miR-34c-3p and miR-34c-5p on SiHa cells proliferation apoptosis, migration and invasion. Biochem. Biophys. Res. Commun. 2011, 409, 513-519.
20. Yang, Z.; Chen, S.; Luan, X.; Li, Y.; Liu, M.; Li, X.; Liu, T.; Tang, H. MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life 2009, 61, 1075-1082.
21. Wang, X.; Wang, H.K.; McCoy, J.P.; Banerjee, N.S.; Rader, J.S.; Broker, T.R.; Meyers, C.; Chow, L.T.; Zheng, Z.M. Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA 2009, 15, 637-647.
22. Wilting, S.M.; Snijders, P.J.; Verlaat, W.; Jaspers, A.; van de Wiel, M.A.; van Wieringen, W.N.; Meijer, G.A.; Kenter, G.G.; Yi, Y.; le Sage, C.; et al. Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis. Oncogene 2013, 32, 106-116.
23. Rao, Q.; Shen, Q.; Zhou, H.; Peng, Y.; Li, J.; Lin, Z. Aberrant microRNA expression in human cervical carcinomas. Med. Oncol. 2012, 29, 1242-1248.
24. Kumar, M.S.; Lu, J.; Mercer, K.L.; Golub, T.R.; Jacks, T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 2007, 39, 673-677.
25. Lee, J.W.; Choi, C.H.; Choi, J.J.; Park, Y.A.; Kim, S.J.; Hwang, S.Y.; Kim, W.Y.; Kim, T.J.; Lee, J.H.; Kim, B.G.; et al. Altered microRNA expression in cervical carcinomas. Clin. Cancer Res. 2008, 14, 2535-2542.
26. Martinez, I.; Gardiner, A.S.; Board, K.F.; Monzon, F.A.; Edwards, R.P.; Khan, S.A. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 2008, 27, 2575-2582.
27. Lui, W.O.; Pourmand, N.; Patterson, B.K.; Fire, A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res. 2007, 67, 6031-6043.
28. Wang, X.; Tang, S.; Le, S.Y.; Lu, R.; Rader, J.S.; Meyers, C.; Zheng, Z.M. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 2008, 3, e2557.
29. Reshmi, G.; Chandra, S.S.; Babu, V.J.; Babu, P.S.; Santhi, W.S.; Ramachandran, S.; Lakshmi, S.; Nair, A.S.; Pillai, M.R. Identification and analysis of novel microRNAs from fragile sites of human cervical cancer: computational and experimental approach. Genomics 2011, 97, 333-340.
30. Li, J.H.; Xiao, X.; Zhang, Y.N.; Wang, Y.M.; Feng, L.M.; Wu, Y.M.; Zhang, Y.X. MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells. Gynecol. Oncol. 2011, 120, 145-151.
31. Wang, L.; Wang, Q.; Li, H.L.; Han, L.Y. Expression of miR-200a, miR-93, metastasis-related gene RECK and MMP2/MMP9 in human cervical carcinoma-Relationship with prognosis. Asian Pac. J. Cancer Prev. 2013, 14, 2113-2118.
32. Lajer, C.B.;Garnaes, E.; Friis-Hansen, L.; Norrild, B.; Therkildsen, H.M.; Glud, M.; Rossing, M.; Lajer, H.; Svane, D.; Skotte, L.; et al. The role of miRNAs in human papilloma virus (HPV)-associated cancers: Bridging between HPV-related head and neck cancer and cervical cancer. Br. J. Cancer 2012, 106, 1526-1534.
33. Muralidhar, B.; Goldstein, L.D.; Ng, G.; Winder, D.M.; Palmer, R.D.; Gooding, E.L.; Barbosa-Morais, N.L.; Mukherjee, G.; Thorne, N.P.; Roberts, I.; et al. Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels. J. Pathol. 2007, 212, 368-377.
34. Muralidhar, B.; Winder, D.; Murray, M.; Palmer, R.; Barbosa-Morais, N.; Saini, H.; Roberts, I.; Pett, M.; Coleman, N. Functional evidence that Drosha overexpression in cervical squamous cell carcinoma affects cell phenotype and microRNA profiles. J. Pathol. 2011, 224, 496-507.
35. Witten, D.; Tibshirani, R.; Gu, S.G.; Fire, A.; Lui, W.O. Ultra-high throughput sequencing-based small RNA discovery and discrete statistical biomarker analysis in a collection of cervical tumours and matched controls. BMC Biol. 2010, 8, 58.
36. Liu, S.; Zhang, P.; Chen, Z.; Liu, M.; Li, X.; Tang, H. MicroRNA-7 downregulates XIAP expression to suppress cell growth and promote apoptosis in cervical cancer cells. FEBS Lett. 2013, 587, 2247-2253.
37. Cheung, T.H.; Man, K.N.; Yu, M.Y.; Yim, S.F.; Siu, N.S.; Lo, K.W.; Doran, G.; Wong, R.R.; Wang, V.W.; Smith, D.I.; et al. Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm. Cell Cycle 2012, 11, 2876-2884.
38. Pereira, P.M.; Marques, J.P.; Soares, A.R.; Carreto, L.; Santos, M.A. MicroRNA expression variability in human cervical tissues. PLoS One 2010, 5, e11780.
39. Long, M.J.; Wu, F.X.; Li, P.; Liu, M.; Li, X.; Tang, H. MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells. Cancer Lett. 2012, 324, 186-196.
40. Ma, D.; Zhang, Y.Y.; Guo, Y.L.; Li, Z.J.; Geng, L. Profiling of microRNA-mRNA reveals roles of microRNAs in cervical cancer. Chin. Med. J. (Engl.) 2012, 125, 4270-4276.
41. Wang, X.; Wang, H.K.; Li, Y.; Hafner, M.; Banerjee, N.S.; Tang, S.; Briskin, D.; Meyers, C.; Chow, L.T.; Xie, X.; et al. microRNAs are biomarkers of oncogenic human papillomavirus infections. Proc. Natl. Acad. Sci. USA 2014, 111, 4262-4267.
42. Wei, Q.; Li, Y.X.; Liu, M.; Li, X.; Tang, H. MiR-17-5p targets TP53INP1 and regulates cell proliferation and apoptosis of cervical cancer cells. IUBMB Life 2012, 64, 697-704.
43. Xu, X.M.; Wang, X.B.; Chen, M.M.; Liu, T.; Li, Y.X.; Jia, W.H.; Liu, M.; Li, X.; Tang, H. MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. Cancer Lett. 2012, 322, 148-158.
44. Kang, H.W.; Wang, F.; Wei, Q.; Zhao, Y.F.; Liu, M.; Li, X.; Tang, H. MiR-20a promotes migration and invasion by regulating TNKS2 in human cervical cancer cells. FEBS Lett. 2012, 586, 897-904.
45. Chen, J.; Yao, D.; Li, Y.; Chen, H.; He, C.; Ding, N.; Lu, Y.; Ou, T.; Zhao, S.; Li, L.; et al. Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int. J. Mol. Med. 2013, 32, 557-567.
46. Zhao, S.; Yao, D.S.; Chen, J.Y.; Ding, N. Aberrant expression of miR-20a and miR-203 in cervical cancer. Asian Pac. J. Cancer Prev. 2013, 14, 2289-2293.
47. Zhang, Y.; Dai, Y.; Huang, Y.; Ma, L.; Yin, Y.; Tang, M.; Hu, C. Microarray profile of micro-ribonucleic acid in tumor tissue from cervical squamous cell carcinoma without human papillomavirus. J. Obstet. Gynaecol. Res. 2009, 35, 842-849.
48. Yeung, C.L.A.; Tsang, T.Y.; Yau, P.L.; Kwok, T.T. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. Oncogene 2011, 30, 2401-2410.
49. Li, Y.; Wang, F.; Xu, J.; Ye, F.; Shen, Y.; Zhou, J.; Lu, W.; Wan, X.; Ma, D.; Xie, X. Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. J. Pathol. 2011, 224, 484-495.
50. Li, B.; Hu, Y.; Ye, F.; Li, Y.; Lv, W.; Xie, X. Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection. Int. J. Gynecol. Cancer 2010, 20, 597-604.
51. Li, B.H.; Zhou, J.S.; Ye, F.; Cheng, X.D.; Zhou, C.Y.; Lu, W.G.; Xie, X. Reduced miR-100 expression in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein. Eur. J. Cancer 2011, 47, 2166-2174.
52. Qin, W.; Dong, P.; Ma, C.; Mitchelson, K.; Deng, T.; Zhang, L.; Sun, Y.; Feng, X.; Ding, Y.; Lu, X.; et al. MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways. Oncogene 2012, 31, 4067-4075.
53. Liu, L.; Yu, X.; Guo, X.; Tian, Z.; Su, M.; Long, Y.; Huang, C.; Zhou, F.; Liu, M.; Wu, X.; et al. MiR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol. Med. Rep. 2012, 5, 753-760.
54. Xing, A.Y.; Wang, B.; Shi, D.B.; Zhang, X.F.; Gao, C.; He, X.Q.; Liu, W.J.; Gao, P. Deregulated expression of miR-145 in manifold human cancer cells. Exp. Mol. Pathol. 2013, 95, 91-97.
55. Liu, J.; Sun, H.; Wang, X.; Yu, Q.; Li, S.; Yu, X.; Gong, W. Increased exosomal microRNA-21 and microRNA-146a levels in the cervicovaginal lavage specimens of patients with cervical cancer. Int. J. Mol. Sci. 2014, 15, 758-773.
56. How, C.; Hui, A.B.; Alajez, N.M.; Shi, W.; Boutros, P.C.; Clarke, B.A.; Yan, R.; Pintilie, M.; Fyles, A.; Hedley, D.W.; et al. MicroRNA-196b regulates the homeobox B7-vascular endothelial growth factor axis in cervical cancer. PLoS One 2013, 8, e67846.
57. Zhu, X.; Er, K.; Mao, C.; Yan, Q.; Xu, H.; Zhang, Y.; Zhu, J.; Cui, F.; Zhao, W.; Shi, H. miR-203 suppresses tumor growth and angiogenesis by targeting VEGFA in cervical cancer. Cell Phys. Biochem. 2013, 32, 64-73.
58. Xie, H.; Zhao, Y.; Caramuta, S.; Larsson, C.; Lui, W.O. MiR-205 expression promotes cell proliferation and migration of human cervical cancer cells. PLoS One 2012, 7, e46990.
59. Wang, F.; Liu, M.; Li, X.; Tang, H. MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett. 2013, 587, 488-495.
60. Yu, J.; Wang, Y.; Dong, R.; Huang, X.; Ding, S.; Qiu, H. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J. Cancer Res. Clin. Oncol. 2012, 138, 671-674.
61. Yamamoto, N.; Kinoshita, T.; Nohata, N.; Itesako, T.; Yoshino, H.; Enokida, H.; Nakagawa, M.; Shozu, M.; Seki, N. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma. Int. J. Oncol. 2013, 42, 1523-1532.
62. Li, Y.; Liu, J.; Yuan, C.; Cui, B.; Zou, X.; Qiao, Y. High-risk human papillomavirus reduces the expression of microRNA-218 in women with cervical intraepithelial neoplasia. J. Int. Med. Res. 2010, 38, 1730-1736.
63. Shen, S.N.; Wang, L.F.; Jia, Y.F.; Hao, Y.Q.; Zhang, L.; Wang, H. Upregulation of microRNA-224 is associated with aggressive progression and poor prognosis in human cervical cancer. Diagn. Pathol. 2013, doi:10.1186/1746-1596-8-69.
64. Bierkens, M.; Krijgsman, O.; Wilting, S.M.; Bosch, L.; Jaspers, A.; Meijer, G.A.; Meijer, C.J.; Snijders, P.J.; Ylstra, B.; Steenbergen, R.D. Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis. Genes Chromosom. Cancer 2013, 52, 56-68.
65. Shen, Y.; Li, Y.; Ye, F.; Wang, F.; Wan, X.; Lu, W.; Xie, X. Identification of miR-23a as a novel microRNA normalizer for relative quantification in human uterine cervical tissues. Exp. Mol. Med. 2011, 43, 358-366.
66. Xu, J.; Li, Y.; Wang, F.; Wang, X.; Cheng, B.; Ye, F.; Xie, X.; Zhou, C.; Lu, W. Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene 2013, 32, 976-987.
67. Zhang, J.; Li, S.; Yan, Q.; Chen, X.; Yang, Y.; Liu, X.; Wan, X. Interferon-β induced microRNA-129-5p down-regulates HPV-18 E6 and E7 viral gene expression by targeting SP1 in cervical cancer cells. PLoS One 2013, 8, e81366.
68. Calin, G.A.; Sevignani, C.; Dumitru, C.D.; Hyslop, T.; Noch, E.; Yendamuri, S.; Shimizu, M.; Rattan, S.; Bullrich, F.; Negrini, M.; et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA 2004, 101, 2999-3004.
69. Schmitz, M.; Driesch, C.; Jansen, L.; Runnebaum, I.B.; Durst, M. Non-random integration of the HPV genome in cervical cancer. PLoS One 2012, 7, e39632.
70. Kraus, I.; Driesch, C.; Vinokurova, S.; Hovig, E.; Schneider, A.; von Knebel Doeberitz, M.; Durst, M. The majority of viral-cellular fusion transcripts in cervical carcinomas cotranscribe cellular sequences of known or predicted genes. Cancer Res. 2008, 68, 2514-2522.
71. Nuovo, G.J.; Wu, X.; Volinia, S.; Yan, F.; di Leva, G.; Chin, N.; Nicol, A.F.; Jiang, J.; Otterson, G.; Schmittgen, T.D.; et al. Strong inverse correlation between microRNA-125b and human papillomavirus DNA in productive infection. Diagn. Mol. Pathol. 2010, 19, 135-143.
72. Soto-Reyes, E.; Gonzalez-Barrios, R.; Cisneros-Soberanis, F.; Herrera-Goepfert, R.; Perez, V.; Cantu, D.; Prada, D.; Castro, C.; Recillas-Targa, F.; Herrera, L.A. Disruption of CTCF at the miR-125b1 locus in gynecological cancers. BMC Cancer 2012, doi:10.1186/1471-2407-12-40.
73. Greco, D.; Kivi, N.; Qian, K.; Leivonen, S.K.; Auvinen, P.; Auvinen, E. Human papillomavirus 16 E5 modulates the expression of host microRNAs. PLoS One 2011, 6, e21646.
74. Yue, C.; Wang, M.; Ding, B.; Wang, W.; Fu, S.; Zhou, D.; Zhang, Z.; Han, S. Polymorphism of the pre-miR-146a is associated with risk of cervical cancer in a Chinese population. Gynecol. Oncol. 2011, 122, 33-37.
75. Wang, F.; Li, Y.; Zhou, J.; Xu, J.; Peng, C.; Ye, F.; Shen, Y.; Lu, W.; Wan, X.; Xie, X. MiR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am. J. Pathol. 2011, 179, 2580-2588.
76. Jazdzewski, K.; Murray, E.L.; Franssila, K.; Jarzab, B.; Schoenberg, D.R.; de la Chapelle, A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc. Natl. Acad. Sci. USA 2008, 105, 7269-7274.
77. Brosh, R.; Shalgi, R.; Liran, A.; Landan, G.; Korotayev, K.; Nguyen, G.H.; Enerly, E.; Johnsen, H.; Buganim, Y.; Solomon, H.; et al. Rotter. p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol. Syst. Biol. 2008, 4, 229.
78. Zheng, Z.M.; Wang, X. Regulation of cellular miRNA expression by human papillomaviruses. Biochim. Biophys. Acta 2011, 1809, 668-677.
79. Cannell, I.G.; Kong, Y.W.; Johnston, S.J.; Chen, M.L.; Collins, H.M.; Dobbyn, H.C.; Elia, A.; Kress, T.R.; Dickens, M.; Clemens, M.J.; et al. p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication. Proc. Natl. Acad. Sci. USA 2010, 107, 5375-5380.
80. Bueno, M.J.; de Cedron, M.G.; Laresgoiti, U.; Fernandez-Piqueras, J.; Zubiaga, A.M.; Malumbres, M. Multiple E2F-induced microRNAs prevent replicative stress in response to mitogenic signaling. Mol. Cell. Biol. 2010, 30, 2983-2995.
81. Woods, K.; Thomson, J.M.; Hammond, S.M. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors, J. Biol. Chem. 2007, 282, 2130-2134.
82. O'Donnell, K.A.; Wentzel, E.A.; Zeller, K.I.; Dang, C.V.; Mendell, J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435, 839-843.
83. Myklebust, M.P.; Bruland, O.; Fluge, O.; Skarstein, A.; Balteskard, L.; Dahl, O. microRNA-15b is induced with E2F-controlled genes in HPV-related cancer. Br. J. Cancer 2011, 105, 1719-1725.
84. Melar-New, M.; Laimins, L.A. Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins. J. Virol. 2010, 84, 5212-5221.
85. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
86. Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A.; et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435, 834-838.
87. Wilting, S.M.; van Boerdonk, R.A.; Henken, F.E.; Meijer, C.J.; Diosdado, B.; Meijer, G.A.; le Sage, C.; Agami, R.; Snijders, P.J.; Steenbergen, R.D. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol. Cancer 2010, 9, 167, doi:10.1186/1476-4598-9-167.
88. Chen, D.; Chen, Z.; Jin, Y.; Dragas, D.; Zhang, L.; Adjei, B.S.; Wang, A.; Dai, Y.; Zhou, X. MicroRNA-99 family members suppress Homeobox A1 expression in epithelial cells. PLoS One 2013, 8, e80625.
89. Cui, F.; Li, X.; Zhu, X.; Huang, L.; Huang, Y.; Mao, C.; Yan, Q.; Zhu, J.; Zhao, W.; Shi, H. MiR-125b inhibits tumor growth and promotes apoptosis of cervical cancer cells by targeting phosphoinositide 3-kinase catalytic subunit delta. Cell Physiol. Biochem. 2012, 30, 1310-1318.
90. Lei, C.; Wang, Y.; Huang, Y.; Yu, H.; Huang, Y.; Wu, L.; Huang, L. Up-regulated miR155 reverses the epithelial-mesenchymal transition induced by EGF and increases chemo-sensitivity to cisplatin in human Caski cervical cancer cells. PLoS One 2012, 7, e52310.
91. Wan, G.; Xie, W.; Liu, Z.; Xu, W.; Lao, Y.; Huang, N.; Cui, K.; Liao, M.; He, J.; Jiang, Y.; et al. Hypoxia-induced MIR155 is a potent autophagy inducer by targeting multiple players in the MTOR pathway. Autophagy 2014, 10, 70-79.
92. Qiang, R.; Wang, F.; Shi, L.Y.; Liu, M.; Chen, S.; Wan, H.Y.; Li, Y.X.; Li, X.; Gao, S.Y.; Sun, B.C.; et al. Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells. Int. J. Biochem. Cell. Biol. 2011, 43, 632-641.
93. Li, J.; Ping, Z.; Ning, H. MiR-218 Impairs Tumor Growth and Increases Chemo-Sensitivity to Cisplatin in Cervical Cancer. Int. J. Mol. Sci. 2012, 13, 16053-16064.
94. Cai, N.; Wang, Y.D.; Zheng, P.S. The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1. RNA 2013, 19, 85-95.
95. Yao, Q.; Xu, H.; Zhang, Q.Q.; Zhou, H.; Qu, L.H. MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. Biochem. Biophys. Res. Commun. 2009, 388, 539-542.
96. Tian, R.Q.; Wang, X.H.; Hou, L.J.; Jia, W.H.; Yang, Q.; Li, Y.X.; Liu, M.; Li, X.; Tang, H. MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis. J. Biol. Chem. 2011, 286, 25556-25563.
97. Tang, T.; Wong, H.K.; Gu, W.; Yu, M.Y.; To, K.F.; Wang, C.C.; Wong, Y.F.; Cheung, T.H.; Chung, T.K.; Choy, K.W. MicroRNA-182 plays an onco-miRNA role in cervical cancer. Gynecol. Oncol. 2013, 129, 199-208.
98. Pang, R.T.; Leung, C.O.; Ye, T.M.; Liu, W.; Chiu, P.C.; Lam, K.K.; Lee, K.F.; Yeung, W.S. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis 2010, 31, 1037-1044.
99. Shi, M.; Du, L.; Liu, D.; Qian, L.; Hu, M.; Yu, M.; Yang, Z.; Zhao, M.; Chen, C.; Guo, L.; et al. Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. J. Pathol. 2012, 228, 148-157.
100. Hu, X.; Schwarz, J.K.; Lewis, J.S., Jr.; Huettner, P.C.; Rader, J.S.; Deasy, J.O.; Grigsby, P.W.; Wang, X. A microRNA expression signature for cervical cancer prognosis. Cancer Res. 2010, 70, 1441-1448.
101. Huang, L.; Lin, J.X.; Yu, Y.H.; Zhang, M.Y.; Wang, H.Y.; Zheng, M. Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix. PLoS One 2012, 7, e33762.
102. Alajez, N.M.; Lenarduzzi, M.; Ito, E.; Hui, A.B.; Shi, W.; Bruce, J.; Yue, S.; Huang, S.H.; Xu, W.; Waldron, J.; et al. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 2011, 71, 2381-2391.
103. He, G.; Wang, Q.; Zhou, Y.; Wu, X.; Wang, L.; Duru, N.; Kong, X.; Zhang, P.; Wan, B.; Sui, L.; et al. YY1 is a novel potential therapeutic target for the treatment of HPV infection-induced cervical cancer by arsenic trioxide. Int. J. Gynecol. Cancer 2011, 21, 1097-1104.
104. Baldwin, A.; Li, W.; Grace, M.; Pearlberg, J.; Harlow, E.; Munger, K.; Grueneberg, D.A. Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells. Proc. Natl. Acad. Sci. USA 2008, 105, 16478-16483.
105. Wang, X.; Meyers, C.; Guo, M.; Zheng, Z.M. Upregulation of p18Ink4c expression by oncogenic HPV E6 via p53-miR-34a pathway. Int. J. Cancer 2011, 129, 1362-1372.
106. Bolos, V.; Grego-Bessa, J.; de la Pompa, J.L. Notch signaling in development and cancer. Endocr. Rev. 2007, 28, 339-363.
107. Naiki, T.; Saijou, E.; Miyaoka, Y.; Sekine, K.; Miyajima, A. TRB2, a mouse Tribbles ortholog, suppresses adipocyte differentiation by inhibiting AKT and C/EBPβ. J. Biol. Chem. 2007, 282, 24075-24082.
108. Grandinetti, K.B.; Stevens, T.A.; Ha, S.; Salamone, R.J.; Walker, J.R.; Zhang, J.; Agarwalla, S.; Tenen, D.G.; Peters, E.C.; Reddy, V.A. Overexpression of TRIB2 in human lung cancers contributes to tumorigenesis through downregulation of C/EBPα. Oncogene 2011, 30, 3328-3335.
109. Keeshan, K.; He, Y.; Wouters, B.J.; Shestova, O.; Xu, L.; Sai, H.; Rodriguez, C.G.; Maillard, I.; Tobias, J.W.; Valk, P.; et al. Tribbles homolog 2 inactivates C/EBPα and causes acute myelogenous leukemia. Cancer Cell 2006, 10, 401-411.
110. Xin, J.X.; Yue, Z.; Zhang, S.; Jiang, Z.H.; Wang, P.Y.; Li, Y.J.; Pang, M.; Xie, S.Y. MiR-99 inhibits cervical carcinoma cell proliferation by targeting TRIB2. Oncol. Lett. 2013, 6, 1025-1030.
111. Zhang, Y.; Liu, Y.; Yang, Y.X.; Xia, J.H.; Zhang, H.X.; Li, H.B.; Yu, C.Z. The expression of PLK-1 in cervical carcinoma: A possible target for enhancing chemosensitivity. J. Exp. Clin. Cancer Res. 2009, doi:10.1186/1756-9966-28-130.
112. Bahassi el, M. Polo-like kinases and DNA damage checkpoint: Beyond the traditional mitotic functions. Exp. Biol. Med. (Maywood) 2011, 236, 648-657.
113. Pillai, M.R.; Halabi, S.; McKalip, A.; Jayaprakash, P.G.; Rajalekshmi, T.N.; Nair, M.K.; Herman, B. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer. Cancer Epidemiol. Biomark. Prev. 1996, 5, 329-335.
114. Dimitrakakis, C.; Kymionis, G.; Diakomanolis, E.; Papaspyrou, I.; Rodolakis, A.; Arzimanoglou, I.; Leandros, E.; Michalas, S. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions. Gynecol. Oncol. 2000, 77, 129-136.
115. Baserga, R. The insulin receptor substrate-1: A biomarker for cancer? Exp. Cell Res. 2009, 315, 727-732.
116. Wei, X.; Xu, H.; Kufe, D. Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene. Cancer Res. 2007, 67, 1853-1858.
117. Shi, T.Y.; Chen, X.J.; Zhu, M.L.; Wang, M.Y.; He, J.; Yu, K.D.; Shao, Z.M.; Sun, M.H.; Zhou, X.Y.; Cheng, X.; et al. A pri-miR-218 variant and risk of cervical carcinoma in Chinese women. BMC Cancer 2013, doi:10.1186/1471-2407-13-19.
118. Wang, Q.; Shu, R.; He, H.; Wang, L.; Ma, Y.; Zhu, H.; Wang, Z.; Wang, S.; Shen, G.; Lei, P. Co-silencing of Birc5 (survivin) and Hspa5 (Grp78) induces apoptosis in hepatoma cells more efficiently than single gene interference. Int. J. Oncol. 2012, 41, 652-660.
119. Sukpan, K.; Settakorn, J.; Khunamornpong, S.; Cheewakriangkrai, C.; Srisomboon, J.; Siriaunkgul, S. Expression of survivin, CD117, and C-erbB-2 in neuroendocrine carcinoma of the uterine cervix. Int. J. Gynecol. Cancer 2011, 21, 911-917.
120. Narayan, G.; Goparaju, C.; Arias-Pulido, H.; Kaufmann, A.M.; Schneider, A.; Durst, M.; Mansukhani, M.; Pothuri, B.; Murty, V.V. Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol. Cancer 2006, doi:10.1186/1471-2407-13-19.
121. Yi, S.; Chen, Y.; Wen, L.; Yang, L.; Cui, G. Expression of connexin 32 and connexin 43 in acute myeloid leukemia and their roles in proliferation. Oncol. Lett. 2012, 4, 1003-1007.
122. Macdonald, A.I.; Sun, P.; Hernandez-Lopez, H.; Aasen, T.; Hodgins, M.B.; Edward, M.; Roberts, S.; Massimi, P.; Thomas, M.; Banks, L; et al. A functional interaction between the MAGUK protein hDlg and the gap junction protein connexin 43 in cervical tumour cells. Biochem. J. 2012, 446, 9-21.
123. Skyldberg, B.; Salo, S.; Eriksson, E.; Aspenblad, U.; Moberger, B.; Tryggvason, K.; Auer, G. Laminin-5 as a marker of invasiveness in cervical lesions. J. Natl. Cancer Inst. 1999, 91, 1882-1887.
124. Kohlberger, P.; Beneder, C.; Horvat, R.; Leodolter, S.; Breitenecker, G. Immunohistochemical expression of laminin-5 in cervical intraepithelial neoplasia. Gynecol. Oncol. 2003, 89, 391-394.
125. Longworth, M.S.; Wilson, R.; Laimins, L.A. HPV31 E7 facilitates replication by activating E2F2 transcription through its interaction with HDACs. EMBO J. 2005, 24, 1821-1830.
126. Brehm, A.; Nielsen, S.J.; Miska, E.A.; McCance, D.J.; Reid, J.L.; Bannister, A.J.; Kouzarides, T. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J. 1999, 18, 2449-2458.
127. Wada, T.; Kikuchi, J.; Furukawa, Y. Histone deacetylase 1 enhances microRNA processing via deacetylation of DGCR8. EMBO Rep. 2012, 13, 142-149.
128. Peralta-Zaragoza, O.; Bermudez-Morales, V.; Gutierrez-Xicotencatl, L.; Alcocer-Gonzalez, J.; Recillas-Targa, F.; Madrid-Marina, V. E6 and E7 oncoproteins from human papillomavirus type 16 induce activation of human transforming growth factor beta1 promoter throughout Sp1 recognition sequence. Viral. Immunol. 2006, 19, 468-480.
129. Lee, Y.J.; Lee, J.E.; Choi, H.J.; Lim, J.S.; Jung, H.J.; Baek, M.C.; Frokiaer, J.; Nielsen, S.; Kwon, T.H. E3 ubiquitin-protein ligases in rat kidney collecting duct: Response to vasopressin stimulation and withdrawal. Am. J. Physiol. Ren. Physiol. 2011, 301, F883-E896.
130. Feng, L.; Allen, N.S.; Simo, S.; Cooper, J.A. Cullin 5 regulates Dab1 protein levels and neuron positioning during cortical development. Genes Dev. 2007, 21, 2717-2730.
131. Lewis, S.P.; Willis, A.N.; Johnson, A.E.; Resau, J.; Burnatowska-Hledin, M.A. Mutational analysis of VACM-1/cul5 exons in cancer cell lines. APMIS 2011, 119, 421-430.
132. Lankat-Buttgereit, B.; Goke, R. The tumour suppressor Pdcd4: Recent advances in the elucidation of function and regulation. Biol. Cell 2009, 101, 309-317.
133. Deftereos, G.; Corrie, S.R.; Feng, Q.; Morihara, J.; Stern, J.; Hawes, S.E.; Kiviat, N.B. Expression of miR-21 and miR-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer. PLoS One 2011, 6, e28423.
134. Harris, T.G.; Burk, R.D.; Yu, H.; Minkoff, H.; Massad, L.S.; Watts, D.H.; Zhong, Y.; Gange, S.; Kaplan, R.C.; Anastos, K.; et al. Insulin-like growth factor axis and oncogenic human papillomavirus natural history. Cancer Epidemiol. Biomark. Prev. 2008, 17, 245-248.
135. Hirano, S.; Ito, N.; Takahashi, S.; Tamaya, T. Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers. Eur. J. Gynaecol. Oncol. 2004, 25, 187-191.
136. Tomasini, R.; Samir, A.A.; Carrier, A.; Isnardon, D.; Cecchinelli, B.; Soddu, S.; Malissen, B.; Dagorn, J.C.; Iovanna, J.L.; Dusetti, N.J. TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J. Biol. Chem. 2003, 278, 37722-37729.
137. Yan, H.L.; Xue, G.; Mei, Q.; Wang, Y.Z.; Ding, F.X.; Liu, M.F.; Lu, M.H.; Tang, Y.; Yu, H.Y.; Sun, S.H. Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J. 2009, 28, 2719-2732.
138. Wang, Y.D.; Cai, N.; Wu, X.L.; Cao, H.Z.; Xie, L.L.; Zheng, P.S. OCT4 promotes tumorigenesis and inhibits apoptosis of cervical cancer cells by miR-125b/BAK1 pathway. Cell Death Dis. 2013, 4, e760.
139. Brockhausen, I. Pathways of O-glycan biosynthesis in cancer cells. Biochim. Biophys. Acta 1999, 1473, 67-95.
140. Peng, R.Q.; Wan, H.Y.; Li, H.F.; Liu, M.; Li, X.; Tang, H. MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-α-D galactosamine: Polypeptide N-acetylgalactosaminyltransferase 7. J. Biol. Chem. 2012, 287, 14301-14309.
141. Vasudevan, S.; Tong, Y.; Steitz, J.A. Switching from repression to activation: Micrornas can up-regulate translation. Science 2007, 318, 1931-1934.
142. Noland, C.L.; Doudna, J.A. Multiple sensors ensure guide strand selection in human RNAi pathways. RNA 2013, 19, 639-648.